“a nonsignificant trend”

The NAC completion rate was 94.2%, with a nonsignificant trend toward a reduced surgical complication rate compared with controls (17.3% versus 22.1%; P = 0.52).

Overall, at 1-month follow-up, there was a nonsignificant trend for improvement in general distress ( t 32 =0.65; P =.52), depressive symptoms ( t 32 =0.75; P =.46), and anxiety symptoms ( t 32 =1.08; P =.29).

There was a nonsignificant trend to more infants BBA to hospital, from 0.50% to 0.57% (aOR, 1.05; 95% CI, 0.91–1.21; P =.52) in the lockdown-exposed group ( Table 3 ).

With regard to choline, there was a nonsignificant trend of lower median (IQR) total intake (PKU: 262.4 mg [188.7, 556.1], non-PKU: 315.8 mg [237.0, 418.4]; Mann Whitney U = 1555, p = 0.53) but higher choline adequacy (Fig. 1 ; PKU: 27.5%, non-PKU: 20%; p = 0.43).

14 A nonsignificant trend toward a survival benefit was observed in favor of letrozole (34 versus 30 months, p = 0.53), however, the absence of a clear survival benefit may reflect the approximately 50% cross-over rate.

The analysis reveals a nonsignificant trend toward reduced procedural success in the CKD group (OR 0.74, 95% CI 0.39–1.41), exhibiting low heterogeneity (Cochran Q = 4.983; df = 6; I 2 = 0%; P = .546).

There was a nonsignificant trend toward a lower miscarriage rate in freeze-all ET (8.9% vs. 11.6%; p = 0.549).

Survival analysis revealed a nonsignificant trend toward greater task persistence in the experimental group ( χ 2 1 =0.36, P =.55).

Motivation exhibited a high baseline level and remained stable over sessions, with no significant effects of impairment group or session, and a nonsignificant trend toward a group-by-session interaction (group: P =.55; session: P =.31; group × session: P =.07).

At the first visit, we observed a nonsignificant trend that the hyposmia group comprised more severe cases than mild cases (27.3% vs 20.5%, P = 0.563) ( Table 1 ).

There was a nonsignificant trend toward a higher median sCRP in patients with high vs. low stage COPD (3.48 vs. 1.64 mg/L, p = 0.565).

examined phase angle in 50 patients with advanced cancer from inpatient units with a median survival of approximately 2 months, and reported that a higher phase angle had a nonsignificant trend toward longer survival (univariate HR 0.81, 95% CI 0.66–1.01, p = .57; multivariate HR 0.79, 95% CI 0.61–1.01, p = .064) [ 15 ].

There was no difference between the TC-325 and hemoclip group in terms of primary hemostasis (94.9% vs 90%; p = 0.487) and there was a nonsignificant trend toward increased rebleeding in the TC-325 group (27.9% vs. 15.8%; p = 0.572) at 1 week.

There was a nonsignificant trend towards decreased antibiotic use in the procalcitonin group (median treatment duration of 9 vs 11 days, P = .58), with no difference in clinical outcomes, despite high (>97%) protocol compliance.

Interestingly a nonsignificant trend was found for longer patient-reported time between patients’ noticing a change in their lesion to initial diagnostic biopsy (5.7 ± 2.0 v 7.1 ± 1.5 months, p = 0.581 ) (Table 3 ).

The outcomes, listed in decreasing order of magnitude, were: abnormal triglyceride levels (aRR 1.28, 95% CI 1.20–1.36; P < .001), abnormal HDL cholesterol levels (aRR 1.24, 95% CI 1.18–1.31; P < .001), abnormal LDL cholesterol levels (aRR 1.19, 95% CI 1.08–1.30; P < .001), total cholesterol levels (aRR 1.14, 95% CI 1.06–1.24; P < .01), and non-HDL cholesterol levels showed a nonsignificant trend (aRR 1.03, 95% CI 0.92–1.17; P = .585).

However, a nonsignificant trend in the median number of days alive and free of dialysis (20 days vs. 11 days; p = 0.59) and in the length of hospital stay (PMX-HP, 22.0 days vs. control 28 days; p = 0.15) was observed between both groups.

There were no significant differences in absenteeism for either treatment group compared with placebo, despite a nonsignificant trend in the monthly fremanezumab administration group (quarterly: −0.1%, p = 0.5918; monthly: −2.1%, p = 0.0873; placebo: 0.8%).

Similar results were observed for recurrence-free survival (RFS), with a nonsignificant trend towards shorter RFS with increasing BMI (126.7 +/- 4.1; 107.3 +/- 5.1; 93.89 +/- 7.3 months respectively; p=0.6).

In group-specific comparisons ( Table 5 ), the High group showed a nonsignificant trend toward reduced risk (HR, 0.81; 95% CI, 0.38-1.75; P = 0.60), and the Low group’s risk was not elevated (HR, 1.04; 95% CI, 0.52-2.12; P = 0.91).

Inversely, AA versus GA ( P = 0.076) showed a nonsignificant trend toward association compared with GG versus GA ( P = 0.613) when p53 somatic mutations were compared.

QF– patients showed a nonsignificant trend toward more frequent CsCMVI (4/10, 40%) compared with QF+ patients (2/9, 22.2%; P = .63).

A nonsignificant trend toward higher scores in the last session was observed in all the other components except anastomosing time (3.4 ± 0.9 vs 3.2 ± 1.0; P = .63).

Tumor intensity ( p = 0.081) demonstrated a nonsignificant trend toward higher values in patients without edema, while sphericity ( p = 0.643), flatness ( p = 0.937), and elongation ( p = 0.189) did not differ between tumors with and without PTBE.

Surgical thromboembolectomy showed a nonsignificant trend toward improved survival (odds ratio (OR), 0.65 (0.24–1.72); P = 0.65) and significantly reduced systemic embolism and composite of mortality and systemic embolism, compared with anticoagulation alone.